BioSig Technologies, Inc. (NASDAQ:BSGM) has announced a partnership with Vuzix Corporation (NASDAQ:VUZI), which will see the medical technology firm deploy Vuzix’s M400 Smart Glasses for remote servicing of its PURE EP System.
The group said the deployment will support the planned nationwide rollout of BioSig’s novel real-time signal processing platform to the large and growing electrophysiology market in the US. The remote servicing support offers an ideal solution for compliance with coronavirus (COVID-19) travel restrictions, it added.
“We are thrilled to work with Vuzix to deploy its outstanding smart glasses solution and enhance our technology offering as we work to accelerate commercialization of our PURE EP System nationwide,” Kenneth L. Londoner, chairman & CEO of BioSig Technologies said in a statement.
READ: BioSig Technologies says its PURE EP System has been installed and first patient cases conducted at Memorial Hospital of South Bend, Indiana
“The Vuzix M400s are the powerful enterprise smart glasses and have compelling clinical applications for digital healthcare. The addition of AR technology to our PURE EP System solution should give us an even greater opportunity to elevate the standard of care in the electrophysiology market,” the BioSig CEO added.
The Vuzix M400 is the next evolution of the industry-leading Vuzix M-Series smart glasses, featuring the new Qualcomm Snapdragon(TM) XR1 platform. Vuzix was hand-selected as one of the initial launch partners for the new Snapdragon XR1 platform, the first purposely built, dedicated XR platform from Qualcomm Technologies. The Snapdragon XR1 microprocessor enables a combination of voice and touchpad navigation for complete control over the device. The M400 Smart Glasses improve processes within many applications such as warehouse logistics, telemedicine, manufacturing, and field service.
Equipped with Vuzix Remote Assist (VRA) software, the M400 Smart Glasses should provide BioSig’s partner physicians and clinicians with quick remote access to technical experts who can assist with servicing the unique hardware architecture and digital modality of PURE EP Systems being utilized in the field. Enterprise use of the M400 Smart Glasses is intended to enable technicians to support BioSig’s systems without the necessity of on-site visits, dramatically decreasing time and expense for both the Company and PURE EP System users.
BioSig plans to explore whether Vuzix Smart Glasses may be used to facilitate remote customer training and provide line-of-sight visualization of intracardiac signals during ablation procedures performed by physicians. In the healthcare industry, Vuzix Smart Glasses are already being used in hospitals and medical centers around the world to perform a wide range of functions, including training, virtual rounds within ICUs, triage in the emergency room and the operating room to guide physicians during surgery, and to provide remote training and mentor remote doctors.
"BioSig’ PURE EP System is an incredibly innovative solution that is tackling a tough problem, and we are proud to support this promising product," added Paul Travers, president and chief executive officer of Vuzix.
“Vuzix has deep experience working with medical and healthcare providers to support applications that have ranged from performing surgeries to telemedicine, patient care, training, remote learning, and much more. We are happy to broaden our support of the healthcare industry by entering the medical device market, particularly the rapidly growing field of bioelectronic medicine.”
Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays, and augmented reality.
The company holds 179 patents and patents pending and numerous IP licenses in the Video Eyewear field and has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2020 and several wireless technology innovation awards among others.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The company’s first product, PURE EPä System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory
Contact the author at email@example.com